In the biotech field, alongside the widely recognized industry giants, some relatively smaller companies focused on specific niches are also demonstrating considerable potential through solid R&D progress and clear market strategies. Axsome Therapeutics (AXSM) and Exelixis (EXEL) are noteworthy representatives among them. Leveraging the successful advancement of their core products and rich R&D pipelines, both companies are poised to achieve excellent financial performance and market returns in the medium term.
Axsome Therapeutics has shown steady performance over the past year, making consistent progress in clinical development, regulatory approvals, and revenue growth. Its core growth driver stems from Auvelity, a drug approved in 2022 for treating major depressive disorder, whose commercialization is proceeding smoothly. Furthermore, Symbravo, the company’s newly approved migraine treatment drug in early 2026, is expected to further drive sales growth. Beyond existing products, Axsome Therapeutics’ late-stage R&D pipeline also holds significant promise. Auvelity’s new indication for Alzheimer’s disease agitation has completed Phase 3 clinical trials and is being actively pursued for approval. Another late-stage candidate drug, AXS-12, targets narcolepsy.
Although its current market capitalization is approximately $7.7 billion, the company estimates that the combined potential peak sales of its marketed and pipeline products across all target indications could exceed $16 billion. This optimistic outlook is underpinned by a precise targeting of vast unmet clinical needs. For instance, Alzheimer’s disease agitation affects over 5 million patients in the U.S., with only one drug currently approved, indicating a broad market space. Multiple candidates in the company’s pipeline share similar characteristics, aiming at therapeutic areas with limited treatment options or urgent demand. Therefore, even after recent solid performance, Axsome Therapeutics’ medium to long-term prospects remain promising.
Exelixis is a biopharmaceutical company focused on developing cancer drugs, with its success built on the core product Cabometyx. This drug has been approved for treating renal cell carcinoma and hepatocellular carcinoma, and can be used as a monotherapy or in combination therapy, supporting steady improvement in the company’s financial performance through ongoing indication expansions. However, some investors have long harbored concerns about its over-reliance on Cabometyx and potential future generic competition. In response, Exelixis has successfully delayed generic market entry until after 2030 through litigation, significantly improving its medium-term outlook.
Simultaneously, the company is actively working to reduce its dependence on a single product by developing new cancer therapies to build a more robust product portfolio. Among these, the investigational drug zanzalintinib for metastatic colorectal cancer (the world’s second-leading cause of cancer death) is particularly crucial. This drug has shown positive results as a combination therapy in Phase 3 clinical trials, and given the urgent need for new treatments in this area, its eventual approval prospects are optimistic. Additionally, Exelixis has several early-stage candidate drugs expected to make progress in the coming years. With Cabometyx sales continuing to grow and new pipelines gradually advancing, the company’s overall growth momentum is likely to drive its stock price towards competitive returns in the next few years.
